Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.12 USD | -0.24% | -2.37% | -39.92% |
Apr. 17 | Evaxion Announces Phase 2 Clinical Trial Update | CI |
Apr. 11 | European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading | MT |
Financials (USD)
Sales 2024 * | 6.27M | Sales 2025 * | 18.26M | Capitalization | 21.49M |
---|---|---|---|---|---|
Net income 2024 * | -11M | Net income 2025 * | -3M | EV / Sales 2024 * | 3.43 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.18 x |
P/E ratio 2024 * |
-2.96
x | P/E ratio 2025 * |
-2.09
x | Employees | 49 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.4% |
Latest transcript on Evaxion Biotech A/S
1 day | -0.24% | ||
1 week | -2.37% | ||
Current month | +28.75% | ||
1 month | +32.90% | ||
3 months | -56.22% | ||
6 months | -39.42% | ||
Current year | -39.92% |
Managers | Title | Age | Since |
---|---|---|---|
Andreas Mattsson
FOU | Founder | - | 08-08-10 |
Niels Møller
FOU | Founder | 46 | 08-08-10 |
Chief Executive Officer | 52 | 23-08-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 54 | 17-12-31 | |
Lars Holtug
BRD | Director/Board Member | 66 | 21-05-24 |
Marianne Søgaard
CHM | Chairman | 56 | 17-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 4.12 | -0.24% | 7,170 |
24-04-24 | 4.13 | -0.24% | 10,156 |
24-04-23 | 4.14 | -1.19% | 25,028 |
24-04-22 | 4.19 | -2.78% | 9,891 |
24-04-19 | 4.31 | +2.13% | 30,943 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.92% | 21.54M | |
+1.12% | 43.84B | |
+6.77% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.01% | 25.53B | |
-24.92% | 18.18B | |
-3.63% | 12.29B | |
+27.16% | 12.29B | |
+7.30% | 11.15B |
- Stock Market
- Equities
- EVAX Stock